License Agreements - Additional Information (Details) - USD ($)	1 Months Ended		3 Months Ended
	Mar. 31, 2026	May 31, 2024	Mar. 31, 2026	Mar. 31, 2025	Dec. 31, 2025
License Agreements [Line Items]
In-process research and development			$ 150,000,000	$ 0
License Agreement \| Novartis Pharma AG
License Agreements [Line Items]
In-process research and development			0	0
Accrued milestone payment as underlying contingencies	$ 0		0		$ 0
License agreement termination date	Jun. 03, 2026
License Agreement \| Guangzhou Joyo Pharmatech Co., Ltd.
License Agreements [Line Items]
Accrued milestone payment as underlying contingencies	$ 0		0		0
License Agreement \| Medshine Discovery Inc.
License Agreements [Line Items]
Accrued milestone payment as underlying contingencies	$ 0		0		$ 0
Joyo License Agreement \| Guangzhou Joyo Pharmatech Co., Ltd.
License Agreements [Line Items]
Upfront payment		$ 12,500,000
Development and regulatory milestone payments obligation if territory expanded		57,500,000
In-process research and development			150,000,000	0
Joyo License Agreement \| Guangzhou Joyo Pharmatech Co., Ltd. \| Maximum
License Agreements [Line Items]
Development and regulatory milestone payments obligation		51,500,000
Commercial milestone payments obligation		125,000,000
Joyo License Agreement \| Guangzhou Joyo Pharmatech Co., Ltd. \| Phase 2 Clinical Trial
License Agreements [Line Items]
Payment for option to expand territory of license on or prior to first dosing of first patient		50,000,000
Payment for option to expand territory of license after first dosing of first patient		150,000,000
Medshine License Agreement \| Medshine Discovery Inc.
License Agreements [Line Items]
Upfront payment		10,000,000
In-process research and development			$ 0	$ 0
Medshine License Agreement \| Medshine Discovery Inc. \| Maximum
License Agreements [Line Items]
Development and regulatory milestone payments obligation		30,000,000
Commercial milestone payments obligation		$ 130,000,000